The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AML
Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the encouraging results of a Phase I/II study (NCT03661307) assessing quizartinib, venetoclax, and decitabine combination therapy in patients with FLT3-ITD mutated acute myeloid leukemia (AML). Dr Yilmaz reports that out of 23 intensive chemotherapy-ineligible older adult patients treated, 21 achieved bone marrow remission, with 80% achieving measurable residual disease (MRD) negativity. At a 2-year follow-up, the median overall survival (OS) has not been reached. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
